SCHEMBL25073032

SCHEMBL25073032

O=S(=O)(Nc1ccc(O)c(Cl)c1)c1cnc(-c2ccc(F)cc2)s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B3 P37058 1/20 0.59
▸ HSD17B2 P37059 1/20 0.59
▸ MAPT P10636 5/20 0.42
▸ TP53 P04637 1/20 0.42
▸ PTPN11 Q06124 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ HPGD P15428 3/20 0.40
▸ ACLY P53396 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ PIK3CD O00329 1/20 0.39
▸ PIK3CG P48736 1/20 0.39
▸ PIK3C3 Q8NEB9 1/20 0.39
▸ MEN1 O00255 5/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ GAA P10253 3/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ GLA P06280 2/20 0.39
▸ NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25073030 0.84 LMNA (0.48) MAPTTP53ALDH1A1HPGDMEN1
SCHEMBL25073280 0.83 PTPN11 (0.45) MAPTPTPN11ALDH1A1HPGDHSD17B10
SCHEMBL25073045 0.83 PFKFB3 (0.50) MAPTPTPN11ALDH1A1HPGDHSD17B10
SCHEMBL25073360 0.80 FABP4 (0.45) HSD17B2MAPTPTPN11ALDH1A1HPGD
SCHEMBL25072418 0.79 PTPN11 (0.44) MAPTPTPN11ALDH1A1HPGDHSD17B10
SCHEMBL25072887 0.79 ALDH1A1 (0.46) MAPTPTPN11ALDH1A1HPGDMEN1
SCHEMBL25073315 0.78 KMT2A (0.49) MAPTPTPN11ALDH1A1HPGDHSD17B10
SCHEMBL25072408 0.78 PTPN11 (0.51) MAPTPTPN11ALDH1A1HPGDMEN1
SCHEMBL30278475 0.78 PTPN11 (0.46) MAPTPTPN11ALDH1A1HPGDMEN1
SCHEMBL25073308 0.77 P4HTM (0.49) MAPTPTPN11ALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 HSD17B3 3/4885HSD17B2 6/4885MAPT 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback